Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Farmers Insurance
Merck
Julphar
Fuji
Covington
Cipla

Generated: August 25, 2019

DrugPatentWatch Database Preview

Claims for Patent: 9,051,561

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,051,561
Title:Asparaginase and treating diseases associated with asparagine dependence
Abstract: Disclosed herein are polypeptides which exhibit asparaginase activity and little to no glutaminase activity. The polypeptides have sequences which correspond to W. succinogenes asparaginase, but have an amino acid residue other than proline at amino acid position 121. The polypeptides exhibit higher kinetic rates of asparaginase activity to glutaminase activity as compared to W. succinogenes asparaginase and Elspar.RTM., an E. coli asparaginase.
Inventor(s): Durden; Donald (La Jolla, CA)
Assignee: Children\'s Hospital Los Angeles (Los Angeles, CA)
Application Number:14/348,637
Patent Claims:1. A recombinantly produced polypeptide comprising an amino acid sequence that corresponds to the protein having SEQ ID NO: 10 and has an amino acid residue other than proline at amino acid position 121, wherein said polypeptide, which has asparaginase activity and exhibits no glutaminase activity or reduced glutaminase activity is expressed in the periplasm of an E. coli host cell.

2. A recombinantly produced polypeptide having an amino acid sequence that has at least 90-100%, 91-100%, 92-100%, 93-100%, 94-100%, 95-100%, 96-100%, 97-100%, 98-100%, 99-100%, or 100% sequence identity to SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, or SEQ ID NO: 4, wherein said polypeptide, which has asparaginase activity and exhibits no glutaminase activity or reduced glutaminase activity is expressed in the periplasm of an E. coli host cell.

3. The recombinantly produced polypeptide of claim 1, and further comprising a signal sequence having SEQ ID NO: 5 or SEQ ID NO: 6.

4. The recombinantly produced polypeptide of claim 1, wherein the amino acid residue is serine, alanine, glycine, cysteine, or threonine.

5. The recombinantly produced polypeptide of claim 1, wherein the polypeptide exhibits a kinetic rate of asparaginase activity that is greater than about 7.5 times that of its kinetic rate of glutaminase activity.

6. An isolated nucleic acid molecule which encodes the polypeptide of claim 1.

7. A host cell which contains the isolated nucleic acid molecule of claim 6.

8. A pharmaceutical composition comprising as an active pharmaceutical ingredient, the polypeptide according to claim 1, and a pharmaceutically acceptable carrier.

9. The pharmaceutical composition according to claim 8, wherein the polypeptide is provided in a therapeutically effective amount for treating a disease which responds to asparagine depletion and/or asparaginase therapy.

10. A method of treating a patient having a disease which comprises administering to the patient a therapeutically effective amount of a recombinantly produced polypeptide according to claim 1 to thereby result in an observable improvement in the clinical symptoms of the disease.

11. A kit which comprises at least one polypeptide according to claim 1 packaged together with a drug delivery device.

12. The recombinantly produced polypeptide of claim 1, wherein an SRP signal sequence was used to express the polypeptide.

13. The recombinantly produced polypeptide of claim 1, wherein a MalE signal sequence was used to express the polypeptide.

14. The recombinantly produced polypeptide of claim 1, wherein a melA promoter was used to express the polypeptide.

15. The recombinantly produced polypeptide of claim 1, wherein a rhaB promoter was used to express the polypeptide.

16. The recombinantly produced polypeptide of claim 1, wherein an SRP signal sequence and a melA promoter was used to express the polypeptide.

17. The recombinantly produced polypeptide of claim 1, wherein the polypeptide exhibits a kinetic rate of asparaginase activity that is 7.6 to about 21.8 times that of its kinetic rate of glutaminase activity.

18. The recombinantly produced polypeptide of claim 1, wherein the polypeptide exhibits a kinetic rate of asparaginase activity that is between 7.5 to 22 times that of its kinetic rate of glutaminase activity.

19. The recombinantly produced polypeptide of claim 2, and further comprising a signal sequence having SEQ ID NO: 5 or SEQ ID NO: 6.

20. The recombinantly produced polypeptide of claim 2, wherein the amino acid residue is serine, alanine, glycine, cysteine, or threonine.

21. The recombinantly produced polypeptide of claim 2, wherein the polypeptide exhibits a kinetic rate of asparaginase activity that is greater than about 7.5 times that of its kinetic rate of glutaminase activity.

22. An isolated nucleic acid molecule which encodes the polypeptide of claim 2.

23. A host cell which contains the isolated nucleic acid molecule of claim 22.

24. A pharmaceutical composition comprising as an active pharmaceutical ingredient, the polypeptide according to claim 2, and a pharmaceutically acceptable carrier.

25. The pharmaceutical composition according to claim 24, wherein the polypeptide is provided in a therapeutically effective amount for treating a disease which responds to asparagine depletion and/or asparaginase therapy.

26. A method of treating a patient having a disease which comprises administering to the patient a therapeutically effective amount of an isolated and/or recombinantly produced polypeptide according to claim 2 to thereby result in an observable improvement in the clinical symptoms of the disease.

27. A kit which comprises at least one polypeptide according to claim 2 packaged together with a drug delivery device.

28. The recombinantly produced polypeptide of claim 2, wherein an SRP signal sequence was used to express the polypeptide.

29. The recombinantly produced polypeptide of claim 2, wherein a MalE signal sequence was used to express the polypeptide.

30. The recombinantly produced polypeptide of claim 2, wherein a melA promoter was used to express the polypeptide.

31. The recombinantly produced polypeptide of claim 2, wherein a rhaB promoter was used to express the polypeptide.

32. The recombinantly produced polypeptide of claim 2, wherein an SRP signal sequence and a melA promoter was used to express the polypeptide.

33. The recombinantly produced polypeptide of claim 2, wherein the polypeptide exhibits a kinetic rate of asparaginase activity that is 7.6 to about 21.8 times that of its kinetic rate of glutaminase activity.

34. The recombinantly produced polypeptide of claim 2, wherein the polypeptide exhibits a kinetic rate of asparaginase activity that is between 7.5 to 22 times that of its kinetic rate of glutaminase activity.

35. The recombinantly produced polypeptide of claim 1 wherein the amino acid residue is serine.

36. The recombinantly produced polypeptide of claim 2 wherein the amino acid residue is serine.

Summary for Patent:   Try a Free Trial

PCT Information
PCT FiledOctober 09, 2012PCT Application Number:PCT/US2012/059379
PCT Publication Date:April 18, 2013PCT Publication Number:WO2013/055699

Details for Patent 9,051,561

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Merck ELSPAR asparaginase VIAL 101063 001 1978-01-10   Try a Free Trial Children\'s Hospital Los Angeles (Los Angeles, CA) 2036-04-30 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Citi
Accenture
Covington
Baxter
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.